vTv Therapeutics Inc Class A
North American company
News & analysis
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.vTv Therapeutics Inc is a biopharmaceutical company engaged in drug discovery and development. Its therapies are intended to treat diseases such as Alzheimer's and type-II diabetes. Its other products include TTP399, type II diabetes drug candidate.
Latest VTVT News